Update on ranolazine in the management of angina

@inproceedings{Codolosa2014UpdateOR,
  title={Update on ranolazine in the management of angina},
  author={J. Nicolas Codolosa and Subroto Acharjee and Vincent M Figueredo},
  booktitle={Vascular health and risk management},
  year={2014}
}
Mortality rates attributable to coronary heart disease have declined in recent years, possibly related to changes in clinical presentation patterns and use of proven secondary prevention strategies. Chronic stable angina (CSA) remains prevalent, and the goal of treatment is control of symptoms and reduction in cardiovascular events. Ranolazine is a selective inhibitor of the late sodium current in myocytes with anti-ischemic and metabolic properties. It was approved by the US Food and Drug… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 57 REFERENCES

and Drug Administration

US Foo
  • FDA approves new treatment for chest pain. Available from: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108587.htm. Accessed February 25,
  • 2014
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Clinical Pharmacokinetics of Ranolazine

  • Clinical pharmacokinetics
  • 2006
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Ranolazine for the suppression of ventricular arrhythmia: a case series.

  • Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
  • 2014
VIEW 1 EXCERPT